AbCellera Results Presentation Deck

Q3 2023 BUSINESS UPDATE COPYRIGHT ABCELLERA 4 PROGRAMS Two AbCellera-led programs advancing into IND-enabling studies. MOLECULE ABCL575 ABCL635 TARGET OX40L undisclosed GPCR or ion channel INDICATION atopic dermatitis undisclosed THERAPEUTIC AREA immunology and inflammation metabolic and endocrine conditions POTENTIAL DIFFERENTIATION best in class first in class POTENTIAL MARKET SIZE $17B by 2032* >$2B * Source: IQVIA

View entire presentation